Pharvaris N.V. received a 'Strong Buy' rating following successful phase 3 trial results for its on-demand and prophylactic therapies for hereditary angioedema (HAE). The RAPIDe-3 trial showed rapid symptom relief with deucrictibant, leading to regulatory submissions to the FDA and EMA. The CHAPTER-3 trial met its primary endpoint, with XR deucrictibant reducing HAE attack rates by 83% compared to placebo, and a new drug application for prophylaxis is expected in the first half of 2027. Key risks include regulatory uncertainties, competition, and the company's cash runway, which may require additional funding within 12 months.
Caleres reported a strong Q3 2026 earnings per share (EPS) of $0.47, surpassing analyst expectations by 27%, signaling improved profitability. However, its revenue of $695.45 million slightly missed estimates despite a 5.6% year-over-year increase, d...
Macy's will report its Q2 fiscal 2026 earnings on September 10, with analysts expecting adjusted EPS of $0.37 and net sales of $4.81 billion, both above company guidance. The retailer's turnaround strategy focuses on strengthening its core stores, gr...
Wells Fargo lowered its price target for Casey's General Stores to $750 from $960 after the company reported a 3.2% same-store sales growth in Q1, missing analyst expectations. Despite the sales miss, Casey's posted revenue of $5.68 billion and EPS o...
America's Car-Mart reported a 57.3% revenue decline to $145.8 million and a net loss of $69 million in Q1 fiscal 2027, driven by capital constraints that limited vehicle purchases and customer financing. Retail unit sales fell 81.9%, and vehicle inve...
J.Jill reported strong Q2 earnings, beating estimates with $1.24 EPS and $154.83M revenue, driven by sales growth and direct sales increase. Following this, BTIG raised its price target to $25, suggesting a 15.74% upside. The company also raised its ...
